MRP1 polymorphisms associated with citalopram response in patients with major depression

Journal of Clinical Psychopharmacology

Volumn 30, Issue 2, 2010, Pages 116-125

  Lee, Sung Hee ^a   Lee, Min Soo ^a   Lee, Ji Hyun ^a   Kim, So Won ^a   Kang, Rhee Hun ^b   Choi, Myoung Jin ^b   Park, Sang Jin ^c   Kim, Se Joo ^a   Lee, Jae Myun ^a   Cole, Susan P C ^d   Lee, Min Goo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Usan Hospital   (South Korea)

^d QUEEN S UNIVERSITY   (Canada)

Author keywords

Abc transporter; Citalopram; Major depressive disorder; MRP1 ABCC1; Remission

Indexed keywords

CITALOPRAM; MULTIDRUG RESISTANCE PROTEIN 1;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952162644     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181d2ef42     Document Type: Article

References (52)

1. Kornstein. SG, Schneider RK. Clinical features of treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 16): 18-25.
2. Souery D, Oswald P, Massat I, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68:1062-1070. (Pubitemid 47340327)
3. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther. 2007;82:606-609. (Pubitemid 47622529)
4. rasmäder K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol. 2004;60: 329-336. (Pubitemid 39062319)
5. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26:180-185. (Pubitemid 38501215)
6. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398-404. (Pubitemid 351178955)
7. Lee G, Dallas S, Hong M, et al. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol Rev. 2001;53:569-596. (Pubitemid 33136238)
8. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650-1654. (Pubitemid 23012438)
9. Conseil G, Deeley RG, Cole SP. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics. 2005;15:523-533. (Pubitemid 41044238)
10. Adachi T, Nakagawa H, Chung I, et al. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol. 2007;6:335-348. (Pubitemid 350104822)
11. de Lange EC. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev. 2004;56:1793-1809.
12. van de Ven R, de Jong MC, Reurs AW, et al. Dendritic cells require multidrug resistance protein. 1 (ABCC1) transporter activity for differentiation. J Immunol. 2006;176:5191-5198.
13. Chang XB. A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev. 2007;26:15-37.
14. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci. 2006;27:438-446.
15. Kubota H, Ishihara H, Langmann T, et al. Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis. Epilepsy Res. 2006;68:213-228. (Pubitemid 43295435)
16. Soontornmalai A, Vlaming ML, Fritschy JM, Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience. 2006;138:159-169. (Pubitemid 43222078)
17. Campbell JD, Koike K, Moreau C, et al. Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP 1. (ABCC1). J Biol Chem. 2004;279:463-468. (Pubitemid 38044847)
18. Koike K, Conseil G, Leslie EM, et al. Identification of proline residues in the core cytoplasmic and transmembrane regions of multidrug resistance protein 1 (MRP1/ABCC1) important for transport function, substrate specificity, and nucleotide interactions. J Biol Chem. 2004;279:12325-12336. (Pubitemid 38445799)
19. Situ D, Haimeur A, Conseil G, et al. Mutational analysis of ionizable residues proximal to the cytoplasmic interface of membrane spanning domain. 3 of the multidrug resistance protein, MRP1 (ABCC1): glutamate 1204 is important for both the expression and catalytic activity of the transporter. J Biol Chem. 2004;279:38871-38880. (Pubitemid 39296047)
20. Conrad S, Kauffmann HM, Ito K, et al. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics. 2002;12:321-330. (Pubitemid 34620660)
21. Kapitany T, Schindl M, Schindler SD, et al. The Citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res. 1999;88:75-88. (Pubitemid 29507522)
22. Baumann P. Pharmacology and pharmacokinetics of Citalopram and other SSRIs. Int Clin Psychopharmacol. 1996;11(suppl 1):5-11. (Pubitemid 126727694)
23. Rochat B, Baumann P, Audus KL. Transport mechanisms for the antidepressant Citalopram in brain microvessel endothelium. Brain Res. 1999;831:229-236. (Pubitemid 29336205)
24. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203-209.
25. Deeley RG, Westlake C, Cole SP. Transmembrane transport of endo- and xenobiotics by mammalian. ATP-binding cassette multidrug resistance proteins. Physiol Rev. 2006;86:849-899. (Pubitemid 44033384)
26. Antonarakis SE. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11:1-3.
27. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
28. Loe DW, Deeley RG, Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998;58: 5130-5136.
29. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034. 1-11.
30. Mathews DH, Disney MD, Childs JL, et al. Incorporating chemical modification constraints into a dynamic programming algorithm for prediction of RNA secondary structure. Proc Natl Acad Sci USA. 2004;101:7287-7292. (Pubitemid 38638025)
31. Griffiths-Jones S, Grocock RJ, van Dongen. S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006:34:4.
32. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: a flexible statistical, power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-191.
33. Renes J, de Vries EG, Nienhuis EF, et al. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol. 1999;126:681-688. (Pubitemid 29087847)
34. Uhr M, Grauer MT. abcb lab P-glycoprotein is involved in the uptake of Citalopram and trimiprarnine into the brain of mice. J Psychiatr Res. 2003;37:179-185. (Pubitemid 36313270)
35. Nikisch G, Mathe AA, Czemik A, et al. Stereoselective metabolism of Citalopram in plasma and cerebrospinal fluid of depressive patients: relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol. 2004;24:283-290. (Pubitemid 38658036)
36. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398-404. (Pubitemid 351178955)
37. Ak H, Ay B, Tanriverdi T, et al. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure. 2007;16:493-503. (Pubitemid 47209238)
38. Mercier C, Masseguin C, Roux F, et al. Expression of P-glycoprotein (ABCB1) and Mrpl (ABCC1) in adult rat brain: focus on astrocytes. Brain Res. 2004; 1021:32-40. (Pubitemid 39158654)
39. Xia Z, Depierre JW, Nässberger L. The tricyclic antidepressants clomipramine and Citalopram induce apoptosis in cultured human lymphocytes. J Pharm Pharmacol. 1996;48:115-116. (Pubitemid 26128696)
40. Xia Z, Lundgren B, Bergstrand A, et al. Changes in the generation of reactive oxygen species and in mitochondrial membrane potential during apoptosis induced by the antidepressants imipramine, clomipramine, and Citalopram and the effects on these changes by Bcl-2 and Bcl-X(L). Biochem Pharmacol. 1999;57: 1199-1208. (Pubitemid 29171696)
41. Wang Z, Sew PH, Ambrose H, et al. Nucleotide sequence analyses of the MRP1 gene in four populations suggest negative selection on its coding region. BMC Genomics. 2006;7:111. (Pubitemid 44018117)
42. Oselin K, Mrozikiewicz PM, Gaikovitch E, et al. Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol. 2003;59:347-350. (Pubitemid 37100355)
43. Fukushima-Uesaka H, Saito Y, Tonkin M, et al. Genetic variations and haplotype structures of the ABC transporter gene ABCC1 in a Japanese population. Drug Metab Pharmacokinet. 2007;22:48-60.
44. Mignone F, Gissi C, Liuni S, et al. Untranslated regions of mRNAs. Genome Biol. 2002;3:reviews0004.1-10.
45. Bertino JR, Banerjee D, Mishra PJ. Pharmacogenomics of microRNA; a miRSNP towards individualized therapy. Pharmacogenomics. 2007;8:1625.
46. Kim VN. MicroRNA. biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005;6:376-385.
47. Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165-173.
48. Long D, Lee R, Williams P, et al. Potent effect of target structure on microRNA function. Nat Struct Mol Biol. 2007;14:287-294. (Pubitemid 46608348)
49. Mishra PJ, Humeniuk R, Longo-Sorbello GS, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA. 2007;104:13513-13518. (Pubitemid 47293976)
50. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905-1917.
51. Lin. E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics. 2008;9:935-946.
52. Laje G, Allen AS, Akula N, et al. Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics. 2009;19:666-674.